Edition:
India

People: Pacira Biosciences Inc (PCRX.OQ)

PCRX.OQ on NASDAQ Stock Exchange Global Select Market

40.53USD
12:20am IST
Change (% chg)

$0.05 (+0.12%)
Prev Close
$40.48
Open
$40.35
Day's High
$40.63
Day's Low
$39.77
Volume
49,670
Avg. Vol
163,009
52-wk High
$54.92
52-wk Low
$35.09

Brege, Laura 

Ms. Laura A. Brege is Independent Director of the Company. Ms. Brege has been Managing Director of Cervantes Life Science Partners, LLC., a health care advisory and consulting company. From September 2012 to July 2015, Ms. Brege served as President and Chief Executive Officer of Nodality, Inc., a privately held biotechnology company focused on oncology and immunology. Previously, Ms. Brege held the roles of Chief Operating Officer, Executive Vice President, Chief Business Officer and Head of Corporate Affairs at Onyx Pharmaceuticals, Inc. ("Onyx"), a biopharmaceutical company that developed and marketed medicines for the treatment of cancer. Prior to joining Onyx in 2006, Ms. Brege was a General Partner at Red Rock Capital Management, a venture capital firm, and Senior Vice President and Chief Financial Officer at COR Therapeutics, Inc. Ms. Brege currently serves as a director of Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), Dynavax Technologies Corporation (Nasdaq: DVAX), HLS Therapeutics, Inc. (TSX: HLS) and Portola Pharmaceuticals, Inc. (Nasdaq: PTLA). She previously served as a member of the board of directors of Angiotech Pharmaceuticals Inc. from 2007 to 2011, Delcath Systems, Inc. from 2012 to 2014 and Aratana Therapeutics, Inc. (Nasdaq: PETX) from February 2014 until March 2019. Ms. Brege earned her undergraduate degree from Ohio University and has an M.B.A. from the University of Chicago.

Basic Compensation

Total Annual Compensation, USD 86,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 119,424
Fiscal Year Total, USD 205,424

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --